Ligand Pharmaceuticals Incorporated (LGND)

NGM – Real Time Price. Currency in USD

293.82

+5.07 (1.75%)

Market open: Aug 12, 2026, 12:06 PM EDT

288.75

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Stock details

Previous close: 288.75$
Day's range: 288.6 - 299.34$
52-week range: 149.51 - 326.63$
Volume: 368 555
Average volume: 289 844
Beta: 0.77
EPS (TTM): 10.01
PE ratio (TTM): 30.87
Forward P/E: 31.19
Market cap: 5 756 407 334
Shares outstanding: 19 935 610
Dividend yield: N/A
Next earnings date: 2026-11-05
Sector: Healthcare
Industry: Biotechnology

About the company

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumon... read more

CEO: Todd Davis
Country: United States
IPO Date: 1992-11-18
Employees: 47
Fiscal Year End: January - December
Website: https://www.ligand.com

Revenue Breakdown

Biopharmaceutical Assets / 100.00%

News

No Data

There are no news for this stock.

Chart: LGND

Loading Chart...

Overall Score

4.9 / 1049%

Octagon View

Strength & Weakness

Cash reserves $0.0 barely cover the upcoming debt maturities $1.1B

Total current assets $0.0 are just enough to cover Total current liabilities $0.0, indicating tight liquidity

Debt-to-equity ratio (1.2) is near the industry average, reflecting balanced leverage

The company has no interest-bearing debt, showcasing excellent financial strength

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	N/A	6.05	1.0
Quick ratio	N/A	5.63	1.0
Debt to Equity	1.16	0.30	6.0
Debt to Assets	0.52	1.04	4.0
Interest coverage	N/A	-16.91	10
Weighted average score			4.4

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	196M	131M	167M	268M	291M
Gross Profit	119M	88M	121M	221M	254M
Operating Income	13M	10M	23M	47M	100M
Net Income	-33M	52M	-4M	124M	197M
EBITDA	56M	47M	60M	81M	117M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	96.91	-11.73	10
Operating margin %	13.49	-24.60	7.0
Net margin %	76.16	-172.20	10
EBITDA margin %	N/A	-201.27	1.0
Cash flow margin %	N/A	-156.39	1.0
Weighted average score			5.8

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	9.78	-57.97	8.0
ROE	14.50	-63.56	7.0
ROIC	10.57	-42.57	7.0
ROCE	1.83	-71.10	4.0
Weighted average score			6.5

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	-32.47	-23.61	1.0
Next quarter	61.44	53.16	10
Current year	7.85	14.08	7.0
Next year	30.82	29.02	10
Weighted average score			7.0

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	23.14	463.49	45.4	5.57	8.8
Y/Y	33.73	900.78	48.12	288.35	10
3y average	18.2	1111.75	61.83	-0.19	7.5
5y average	13.09	1038.21	37.1	22.07	9.5
Weighted average score					9.0

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	30.42	-5.25	4.0
PEG (5yr expected)	1.53	0.27	5.0
P/S	21.80	64.66	5.8
P/B	6.09	2.96	2.8
Weighted average score			4.4

DCF Model

DCF Model Period5 years

Discount rate10.16%

Perpetual growth rate3%

Revenue 5 year CAGR16.87%

FCF 5 year CAGR4

Fair value141.08$

Stock price292.85$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$141.08

UndervaluedStock priceOvervalued

$292.85

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Todd Davis

Country

United States

IPO Date

1992-11-18

Employees

Fiscal Year End

January - December

Website

https://www.ligand.com

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

N/A

6.05

1.0

Quick ratio

N/A

5.63

1.0

Debt to Equity

1.16

0.30

6.0

Debt to Assets

0.52

1.04

4.0

Interest coverage

N/A

-16.91

Weighted average score

4.4

METRIC

2022

2023

2024

2025

TTM

Total Revenue

196M

131M

167M

268M

291M

Gross Profit

119M

88M

121M

221M

254M

Operating Income

13M

10M

23M

47M

100M

Net Income

-33M

52M

-4M

124M

197M

EBITDA

56M

47M

60M

81M

117M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

96.91

-11.73

Operating margin %

13.49

-24.60

7.0

Net margin %

76.16

-172.20

EBITDA margin %

N/A

-201.27

1.0

Cash flow margin %

N/A

-156.39

1.0

Weighted average score

5.8

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

9.78

-57.97

8.0

ROE

14.50

-63.56

7.0

ROIC

10.57

-42.57

7.0

ROCE

1.83

-71.10

4.0

Weighted average score

6.5

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

-32.47

-23.61

1.0

Next quarter

61.44

53.16

Current year

7.85

14.08

7.0

Next year

30.82

29.02

Weighted average score

7.0

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

23.14

463.49

45.4

5.57

8.8

Y/Y

33.73

900.78

48.12

288.35

3y average

18.2

1111.75

61.83

-0.19

7.5

5y average

13.09

1038.21

37.1

22.07

9.5

Weighted average score

9.0

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

30.42

-5.25

4.0

PEG (5yr expected)

1.53

0.27

5.0

P/S

21.80

64.66

5.8

P/B

6.09

2.96

2.8

Weighted average score

4.4

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Ligand Pharmaceuticals Incorporated (LGND)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ligand Pharmaceuticals Incorporated (LGND)

Stock details

About the company

Revenue Breakdown

News

Chart: LGND

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$141.08

$292.85

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: LGND

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$141.08

$292.85

Economic Moat